Comparative investigation of pulmonary vasodilating effects of inhaled Nitric Oxide (NO) gas therapy and inhalation of SIN-1, a new drug formulation containing an NO-donor metabolite

Back

ESC Professional Premium Access

Comparative investigation of pulmonary vasodilating effects of inhaled Nitric Oxide (NO) gas therapy and inhalation of SIN-1, a new drug formulation containing an NO-donor metabolite

Session: Current treatment of pulmonary hypertension: it is all about vasodilators

Topic: Pharmacotherapy

Speaker: Doctor A. Olah (Budapest, HU)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Attila Olah

Semmelweis University, Budapest (Hungary)

1 presentation

0 follower

7 more presentations in this session

Effect of a short course of parenteral treprostinil therapy on right heart structure and function in pulmonary arterial hypertension

Speaker: Doctor C. Vizza (Rome, IT)

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

Speaker: Doctor M. Pentikainen (Helsinki, FI)

Macitentan tadalafil Fixed Dose Combination (FDC) in treatment-naive and prior monotherapy patients with Pulmonary Arterial Hypertension (PAH): insights from A DUE

Speaker: Professor P. Jansa (Prague, CZ)

The effect of sildenafil on maternal mortality in pulmonary arterial hypertension associated with congenital heart disease

Speaker: Doctor N. Nahdi (Yogyakarta, ID)

Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension

Speaker: Doctor G. martini (Bologna, IT)

Access the full session

Current treatment of pulmonary hypertension: it is all about vasodilators

Speakers: Doctor A. Olah, Doctor C. Vizza, Doctor M. Pentikainen, Professor P. Jansa, Doctor N. Nahdi...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Comparative investigation of pulmonary vasodilating effects of inhaled Nitric Oxide (NO) gas therapy and inhalation of SIN-1, a new drug formulation containing an NO-donor metabolite

About the speaker

Doctor Attila Olah

7 more presentations in this session

Effect of a short course of parenteral treprostinil therapy on right heart structure and function in pulmonary arterial hypertension

Triple therapy for incident pulmonary arterial hypertension in Finland between 2008 and 2020. A descriptive real-world FINPAH cohort study

Macitentan tadalafil Fixed Dose Combination (FDC) in treatment-naive and prior monotherapy patients with Pulmonary Arterial Hypertension (PAH): insights from A DUE

The effect of sildenafil on maternal mortality in pulmonary arterial hypertension associated with congenital heart disease

Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension

Access the full session

Current treatment of pulmonary hypertension: it is all about vasodilators

About the event

ESC Congress 2023

ESC 365 is supported by